Investors & Media
Bardoxolone methyl
Bardoxolone methyl, previously known as RTA 402,
is the lead molecule in Reata's portfolio of
AIMs
Image by Wyman Meinzer
2011
12.12.2011
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modulators11.29.2011
New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System10.14.2011
Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors06.24.2011
New Phase 2 Data Published in New England Journal of Medicine Shows Bardoxolone Methyl Sustained Improvement in Measure of ...06.16.2011
Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes
2010
11.20.2010
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl11.11.2010
Reata to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics with CKD in Late-Breaking Session at ASN Renal Week Conference09.23.2010
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.07.12.2010
Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methyl06.09.2010
Reata to Present at Jefferies 2010 Global Life Sciences Conference on 6/10/2010 at 1 P.M. EST Reata to Present at Jefferies 2010 Global Life Sciences Conference. Presentation scheduled for Thursday, June 10th at 1 p.m. EST04.18.2010
Reata Announces Presentation of Bardoxolone Methyl Data at the National Kidney Foundation (NKF) 2010 Spring Clinical Meetings01.08.2010
Reata to Present at J.P. Morgan Conference on 1/14 at 1:00 PST01.07.2010
Reata Pharmaceuticals Licenses CKD Drug to Kyowa Hakko Kirin for Asian Markets
2009
12.03.2009
Reata Pharmaceuticals, Inc. announces the company's recent participation at the investor conferences.11.01.2009
Reata Presents Bardoxolone Methyl Data at the American Society of Nephrology Renal Week 200909.04.2009
Reata to Present at Thomas Weisel Partners 2009 Healthcare Conference08.05.2009
Reata Presents at BMO Capital Markets Conference06.06.2009
Reata Presents Promising Data on Bardoxolone at American Diabetes Association Annual Scientific Meeting.03.25.2009
Reata Completes Financing and Expands Team to Capture Opportunity Created by Encouraging Clinical Data in Chronic Kidney Disease; Late Stage Trial Initiated in Patients with Advanced CKD.02.18.2009
Reata's AIM Shows Promise for COPD in Study Published in Proceedings of the National Academy of Sciences.
2008
10.28.2008
Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Thursday, October 30, 2008 at the 7th Annual BIO Investor Forum at 11:30 a.m., Pacific Time.10.15.2008
FDA Grants Orphan Drug Status to Reata's RTA 402 for Treatment of Pancreatic Cancer09.03.2008
Reata Pharmaceuticals, Inc. announces that its Vice President of Finance, Jason Wilson, will be presenting a company overview at the Thomas Weisel Partners Healthcare Conference.07.28.2008
Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview at the BMO Capital Markets "Focus on Healthcare Conference."06.18.2008
IRVING, TX -- June 18, 2008 -- Reata Pharmaceuticals, Inc. announced a substantial expansion of its executive team to take advantage of opportunities from its advancing clinical and preclinical pipelines.06.01.2008
IRVING, TX -- June 1, 2008 -- Reata Pharmaceuticals, Inc. announced results from a first-in-man study of RTA 402 in patients with advanced cancers at the annual meeting of the American Society for Clinical Oncology.05.27.2008
IRVING, TX -- May 27, 2008 -- Reata announces that CEO, Warren Huff, will be presenting on Reata’s two franchise technologies at the FBR Capital Markets 12th Annual Spring Investor Conference.05.22.2008
IRVING, TX -- May 22, 2008 -- Reata Pharmaceuticals, Inc. announced the publication of 10 separate peer-reviewed papers supporting the use of its Antioxidant Inflammation Modulators (AIMs) in cancer patients.05.21.2008
Results of a Phase 1 clinical trial of RTA 402 in patients with advanced cancers was selected for an oral presentation at the 2008 annual meeting of the American Society of Clinical Oncologists.02.08.2008
Reata announces CEO, Warren Huff, will be presenting at the Biotechnology Industry Organization's CEO and Investor Conference04.11.2008
Updated Data on Reata's Two Clinical Candidates Presented at 2008 Annual Meeting of the American Association of Cancer Research. Reata Collaborators Present Five Posters on RTA 402 and Berubicin04.09.2008
IRVING, TX -- April 9, 2008 -- Reata Pharmaceuticals, Inc. announced today the presentation of significant new preclinical data on its two clinical-stage compounds
Archive
09.16.2003
Reata Pharmaceuticals, Inc. ("Reata") announced the completion of a series of exclusive patent licenses with The University of Texas Southwestern Medical Center at Dallas ("UT Southwestern").11.01.2004
Reata Pharmaceuticals, Inc. announced the completion of a license agreement providing Reata with exclusive worldwide rights to a promising new class of anticancer compounds.11.11.2004
Reata Pharmaceuticals, Inc. announced the closing of a $12.0 million private financing round.03.22.2005
Reata Pharmaceuticals, Inc. announced the publication of a new paper demonstrating the antiinflammatory properties of its synthetic triterpenoids.05.02.2005
Reata Pharmaceuticals, Inc. today announced a name change as well as RTA 744 has received FDA clearance to begin clinical testing in patients.05.10.2005
Reata Pharmaceuticals, Inc. ("Reata") announced the completion of a license agreement providing Reata with exclusive worldwide rights to a promising new class of anticancer compounds.06.01.2005
Reata Pharmaceuticals, Inc. announced that Charles A. Sanders, M.D. has been named to the Company's Board of Directors.10.12.2005
Reata Pharmaceuticals, Inc. today announced that RTA 401 has received FDA clearance to begin clinical testing in patients.11.03.2005
Reata Pharmaceuticals, Inc. announced that it has been awarded a Phase I grant by the Small Business Innovation Research (SBIR) Program of the National Institutes of Health (NIH).11.04.2005
Reata Pharmaceuticals, Inc. announced that researchers have presented results that one of Reata's synthetic triterpenoids significantly reduced the formation and growth of liver tumors in rats.11.14.2005
Reata Pharmaceuticals, Inc. announced the presentation of significant data on its clinical, preclinical, and discovery programs during the joint EORTC-AACR-NCI International Conference.02.17.2006
Reata Pharmaceuticals, Inc. announced the publication of preclinical study results showing that one of Reata's synthetic triterpenoids significantly reduced the formation and growth of liver tumors in rats.04.05.2006
Reata Pharmaceuticals, Inc. announced the publication of a new paper demonstrating that RTA 402 was shown to suppress NF-kB activity by inhibiting the activation of I-kappa-Ba kinase (IKK).04.06.2006
Reata Pharmaceuticals, Inc. announced that RTA 402, has received FDA clearance to begin clinical testing in patients.04.17.2006
Reata Pharmaceuticals, Inc. announced the completion of a license agreement providing Reata with rights to a new class of anti-inflammatory compounds known as the tricyclic bis-enones (TBEs).06.21.2006
Reata Pharmaceuticals, Inc. announced that it will present an overview of the company and its development programs at the Jefferies Life Sciences Conference.08.04.2006
Reata Pharmaceuticals, Inc announced the closing of a $22.6 million private financing round.10.26.2006
Reata Pharmaceuticals, Inc. announced that the FDA has granted Reata's request for orphan drug designation for RTA 744.11.10.2006
Reata Pharmaceuticals, Inc. announced interim results from its ongoing Phase 1 trial of RTA 744 in advanced primary brain tumors.11.15.2006
Reata Pharmaceuticals, Inc. announced the presentation of preclinical data showing that RTA 402 prevented the development of lung cancer in an established mouse model of the disease.04.25.2007
Reata Pharmaceuticals, Inc. announced the publication of a review covering the company's Synthetic Triterpenoid programs in the journal "Nature Reviews Cancer."05.15.2007
Reata Pharmaceuticals, Inc. announced the publication of an article in journal "Cancer Research" showing that RTA 402 was highly effective in a rigorous animal model of breast cancer.07.06.2007
Reata Pharmaceuticals, Inc announced the closing of a $25.0 million private financing round.06.28.2007
Reata Pharmaceuticals, Inc. announced the presentation of new preclinical data showing RTA 402 is effective at protecting against common toxicities caused by traditional cancer treatments.10.18.2007
Reata Pharmaceuticals, Inc. announced that RTA 402 has been selected as one of the top 10 most promising cancer drugs in development and available for strategic partnering.10.24.2007
Reata Pharmaceuticals, Inc. announced the presentation of results from a Phase I cancer trial of RTA 402 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.
